(Q34057799)

30 July 2017

1 reference

title

TGF-beta-based immunotherapy for cancer: breaching the tumor firewall (English)

1 reference

30 July 2017

1 reference

Shah AH

1 reference

30 July 2017

Lee C

series ordinal

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

167-172

1 reference

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

T cell defined tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

The transforming growth factor-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

The host-tumor immune conflict: from immunosuppression to resistance and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Induction of anti-self-immunity to cure cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Tumor immunology: the glass is half full

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Dendritic cell-based immunotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

DNA-based immunization by in vivo transfection of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Intratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C167%3A%3AAID-PROS11%3E3.0.CO%3B2-J

10.1002/1097-0045(20001001)45:2<167::AID-PROS11>3.0.CO;2-J

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference